These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26428513)

  • 1. TAS-102, a novel antitumor agent: a review of the mechanism of action.
    Lenz HJ; Stintzing S; Loupakis F
    Cancer Treat Rev; 2015 Nov; 41(9):777-83. PubMed ID: 26428513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
    Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
    Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
    Miyamoto Y; Lenz HJ; Baba H
    Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
    Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
    Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
    Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
    Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAS-102: a novel antimetabolite for the 21st century.
    Uboha N; Hochster HS
    Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 12. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
    Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.
    Matsuoka K; Nakagawa F; Kobunai T; Takechi T
    Oncotarget; 2018 Mar; 9(17):13438-13450. PubMed ID: 29568368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
    Becerra CR; Yoshida K; Mizuguchi H; Patel M; Von Hoff D
    J Clin Pharmacol; 2017 Jun; 57(6):751-759. PubMed ID: 28070894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
    Baba T; Kokuryo T; Yamaguchi J; Yokoyama Y; Uehara K; Ebata T; Nagino M
    Anticancer Res; 2018 Mar; 38(3):1427-1434. PubMed ID: 29491068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
    Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.